Merck Sharp + Dohme Corp.

Cyclerion Therapeutics, Inc.

Ironwood Pharmaceuticals, Inc.

Msd K.k.

Tisento Therapeutics Inc.

Joon Jung

Rajesh R Iyengar

Thomas Wai-Ho Lee

Paul A Renhowe

Glen Robert Rennie

Takashi Nakai

Ara Mermerian

Timothy Claude Barden

Nicholas Robert Perl

James Edward Sheppeck

Mark G Currie

Xiang Y Yu

Joel D Moore

Lei Jia

Christopher J Dinsmore

Jason D Brubaker

Hongjun Zhang

Philip Jones

Joshua Close

Jonathan R Young

Tony Siu

Mark E Scott

Neville J Anthony

David James Witter

Phieng Siliphaivanh

Solomon D Kattar

David Joseph Guerin

Jason David Katz

John W Butcher

Matthew Christopher

Anandan Palani

Robert G Aslanian

Michael D Altman

Xianhai Huang

Scott D Edmondson

Dong-Ming Shen

Kevin D McCormick

Kevin J Wilson

Ying Huang

Alan B Northrup

Cheng Zhu

Gregori J Morriello

G-Yoon Jamie Im

Karthik Iyer

Colleen Hudson

Kimberly Kafadar Long

George Todd Milne

Kim Tang

James Jia

Peter Germano

Michelle Martinez

Rachel Nicola MacCoss

Hyun Chong Woo

Scott Peterson

Luis E Torres

Alexey A Rivkin

Graham Frank Smith

Carolyn Michele Cammarano

Sean P Ahearn

Dawn Marie Hoffman

Purakkattle J Biju

Christopher Francis Thompson

James Patrick Jewell

Feng Shi

Catherine M White

Matthew Lloyd Childers

Wei Zhou

Qinglin Pu

Lehua Chang

Satoru Ito

Brandon D Cash

Nam Fung Kar

Ning Shao

Zhongyong Wei

Li Dong

June J Kim

Christopher R Moyes

Duan Liu

Joshua T Close

John T Hendrix

Kevin A Keenan

Ekaterina Kozina

Nicholas Perl

Gergori J Morriello

Yongquan Hou

Elizabeth Stanton

Maria D Ribadeneira

Raksha Archarya

Dawn Marie Mampreian Hoffman

Paul Allen Renhowe

Mark Currie

Paul Allan Renhowe

John Hendrix

Christopher J Moyes

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula I:

sGC stimulators

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable. The compounds are of Formula I:

SGC stimulators

The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3',5&#x2032;-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.

Treatment of CNS diseases with sGC stimulators

Compounds of Formulae I' and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed. 

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I). 

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable. The compounds are of Formula I: 

The present patent application discloses at least the compounds according to Formula I' shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, J, n, J, J, X, Z, Z, R, R, Y, R, o and W are as defined herein.

The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

Acyclic cyanoethylpyrazoles as janus kinase inhibitors

Cyanomethylpyrazole carboxamides as janus kinase inhibitors

Growing community of inventors

Newton, MA, United States of America

Joon Jung